Richard Ghalie
Technik-/Wissenschafts-/F&E-Leiter bei MEI PHARMA, INC.
Vermögen: 4 483 $ am 30.04.2024
Aktive Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| David Urso | M | 60 | 10 Jahre | |
| Ivor Royston | M | 79 |
Favrille, Inc.
Viracta Subsidiary, Inc.
 Viracta Subsidiary, Inc. BiotechnologyHealth Technology Viracta Subsidiary, Inc. engages in the development of proprietary viral gene activation therapy to address cancers associated with the Epstein-Barr virus. Its platform is designed as a targeted approach to treat a range of viral-associated cancers and other serious diseases. The company was founded by Ronald J. Berenson, Douglas V. Faller, George C. Hillman, Thalia Papayannopoulou, Susan P. Perrine, George Stamatoyannopoulos, and Robert Williams and is headquartered in Cardiff, CA. | 10 Jahre |
| Justin File | M | 53 | 1 Jahre | |
| Charles Baltic | M | 63 | 13 Jahre | |
| Nick Glover | M | 55 | 11 Jahre | |
| Fred Driscoll | M | 73 | 6 Jahre | |
| David Walsey | M | - | 6 Jahre | |
| Roger Pomerantz | M | 67 |
Viracta Subsidiary, Inc.
Viracta Subsidiary, Inc. BiotechnologyHealth Technology Viracta Subsidiary, Inc. engages in the development of proprietary viral gene activation therapy to address cancers associated with the Epstein-Barr virus. Its platform is designed as a targeted approach to treat a range of viral-associated cancers and other serious diseases. The company was founded by Ronald J. Berenson, Douglas V. Faller, George C. Hillman, Thalia Papayannopoulou, Susan P. Perrine, George Stamatoyannopoulos, and Robert Williams and is headquartered in Cardiff, CA. | 4 Jahre |
| Jim Woody | M | 81 |
Viracta Subsidiary, Inc.
Viracta Subsidiary, Inc. BiotechnologyHealth Technology Viracta Subsidiary, Inc. engages in the development of proprietary viral gene activation therapy to address cancers associated with the Epstein-Barr virus. Its platform is designed as a targeted approach to treat a range of viral-associated cancers and other serious diseases. The company was founded by Ronald J. Berenson, Douglas V. Faller, George C. Hillman, Thalia Papayannopoulou, Susan P. Perrine, George Stamatoyannopoulos, and Robert Williams and is headquartered in Cardiff, CA. | - |
| Jason Aryeh | M | 55 | 18 Jahre | |
| Thomas Reynolds | M | 65 | 11 Jahre | |
| John Kozarich | M | 74 | 21 Jahre | |
| Gur Roshwalb | M | 55 |
Viracta Subsidiary, Inc.
Viracta Subsidiary, Inc. BiotechnologyHealth Technology Viracta Subsidiary, Inc. engages in the development of proprietary viral gene activation therapy to address cancers associated with the Epstein-Barr virus. Its platform is designed as a targeted approach to treat a range of viral-associated cancers and other serious diseases. The company was founded by Ronald J. Berenson, Douglas V. Faller, George C. Hillman, Thalia Papayannopoulou, Susan P. Perrine, George Stamatoyannopoulos, and Robert Williams and is headquartered in Cardiff, CA. | 4 Jahre |
| Daniel Chevallard | M | 44 |
Viracta Subsidiary, Inc.
Viracta Subsidiary, Inc. BiotechnologyHealth Technology Viracta Subsidiary, Inc. engages in the development of proprietary viral gene activation therapy to address cancers associated with the Epstein-Barr virus. Its platform is designed as a targeted approach to treat a range of viral-associated cancers and other serious diseases. The company was founded by Ronald J. Berenson, Douglas V. Faller, George C. Hillman, Thalia Papayannopoulou, Susan P. Perrine, George Stamatoyannopoulos, and Robert Williams and is headquartered in Cardiff, CA. | 5 Jahre |
| Anne Frese | F | - | 2 Jahre | |
| Michael Huang | M | 50 |
Viracta Subsidiary, Inc.
Viracta Subsidiary, Inc. BiotechnologyHealth Technology Viracta Subsidiary, Inc. engages in the development of proprietary viral gene activation therapy to address cancers associated with the Epstein-Barr virus. Its platform is designed as a targeted approach to treat a range of viral-associated cancers and other serious diseases. The company was founded by Ronald J. Berenson, Douglas V. Faller, George C. Hillman, Thalia Papayannopoulou, Susan P. Perrine, George Stamatoyannopoulos, and Robert Williams and is headquartered in Cardiff, CA. | 5 Jahre |
| Steven Wood | M | 41 | 1 Jahre | |
| Taheer Mehboob Datoo | M | 33 | 1 Jahre | |
| Sam Murphy | M | 47 |
Viracta Subsidiary, Inc.
Viracta Subsidiary, Inc. BiotechnologyHealth Technology Viracta Subsidiary, Inc. engages in the development of proprietary viral gene activation therapy to address cancers associated with the Epstein-Barr virus. Its platform is designed as a targeted approach to treat a range of viral-associated cancers and other serious diseases. The company was founded by Ronald J. Berenson, Douglas V. Faller, George C. Hillman, Thalia Papayannopoulou, Susan P. Perrine, George Stamatoyannopoulos, and Robert Williams and is headquartered in Cardiff, CA. | 5 Jahre |
| Eugene Park | M | - | 3 Jahre | |
| Jason Sausser | M | - | 2 Jahre | |
| Eric Deng | M | - | 3 Jahre | |
| Caroline Ruiz | F | - | 2 Jahre | |
| James Flynn | M | 43 | 1 Jahre |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Steven Gillis | M | 71 |
Immunex Corp.
 Immunex Corp. BiotechnologyHealth Technology Immunex Corporation is a leading biopharmaceutical company dedicated to improving lives through immune system science innovation | 13 Jahre |
| Thomas M. Zech | M | 72 | 7 Jahre | |
| Richard L. Anderson | M | 84 | 5 Jahre | |
| Douglass Given | M | 71 | 2 Jahre | |
| John P. Longenecker | M | 76 |
Favrille, Inc.
| 7 Jahre |
| Christine Anna White | M | 72 | 13 Jahre | |
| Pete de Spain | M | - |
Favrille, Inc.
| 7 Jahre |
| Brian Drazba | M | 63 | 6 Jahre | |
| Daniel Gold | M | 70 | 13 Jahre | |
| Peggy Phillips | F | 70 |
Immunex Corp.
Immunex Corp. BiotechnologyHealth Technology Immunex Corporation is a leading biopharmaceutical company dedicated to improving lives through immune system science innovation | 6 Jahre |
| Ofir Moreno | M | - | 12 Jahre | |
| Leah Cann | F | 63 | 7 Jahre | |
| David Eric Robinson | M | - | - | |
| Tamar Howson | F | 75 | 4 Jahre | |
| Cheryl Cohen | F | 58 | 2 Jahre | |
| Tamara Favorito | F | 65 |
Favrille, Inc.
| 8 Jahre |
| Edward V. Fritzky | M | 73 |
Immunex Corp.
Immunex Corp. BiotechnologyHealth Technology Immunex Corporation is a leading biopharmaceutical company dedicated to improving lives through immune system science innovation | 8 Jahre |
| Paul G. Abrams | M | - | 11 Jahre | |
| Michael K. Jackson | M | 74 | - | |
| Sujay Kango | M | 60 | 2 Jahre | |
| Kevan E. Clemens | M | 80 | 7 Jahre | |
| Jamie A. Tereschuck | F | - | - | |
| Dawn Viveash | M | 68 |
Immunex Corp.
Immunex Corp. BiotechnologyHealth Technology Immunex Corporation is a leading biopharmaceutical company dedicated to improving lives through immune system science innovation | 2 Jahre |
| Barry Simon | M | 59 |
Viracta Subsidiary, Inc.
Viracta Subsidiary, Inc. BiotechnologyHealth Technology Viracta Subsidiary, Inc. engages in the development of proprietary viral gene activation therapy to address cancers associated with the Epstein-Barr virus. Its platform is designed as a targeted approach to treat a range of viral-associated cancers and other serious diseases. The company was founded by Ronald J. Berenson, Douglas V. Faller, George C. Hillman, Thalia Papayannopoulou, Susan P. Perrine, George Stamatoyannopoulos, and Robert Williams and is headquartered in Cardiff, CA. | 3 Jahre |
| Alejandro Ricart | M | - | 1 Jahre | |
| Brian Powl | M | 50 | - | |
| Thomas Daniel | M | 70 |
Immunex Corp.
Immunex Corp. BiotechnologyHealth Technology Immunex Corporation is a leading biopharmaceutical company dedicated to improving lives through immune system science innovation | 2 Jahre |
| Naj Allana | M | 63 |
Favrille, Inc.
| - |
| David Slack | M | 61 |
Viracta Subsidiary, Inc.
Viracta Subsidiary, Inc. BiotechnologyHealth Technology Viracta Subsidiary, Inc. engages in the development of proprietary viral gene activation therapy to address cancers associated with the Epstein-Barr virus. Its platform is designed as a targeted approach to treat a range of viral-associated cancers and other serious diseases. The company was founded by Ronald J. Berenson, Douglas V. Faller, George C. Hillman, Thalia Papayannopoulou, Susan P. Perrine, George Stamatoyannopoulos, and Robert Williams and is headquartered in Cardiff, CA. | 4 Jahre |
| Todd Butler | M | - | 2 Jahre | |
| Hector V. Barreto | M | 62 |
Favrille, Inc.
| - |
| Daniel J. Burge | M | 62 |
Immunex Corp.
Immunex Corp. BiotechnologyHealth Technology Immunex Corporation is a leading biopharmaceutical company dedicated to improving lives through immune system science innovation | 2 Jahre |
| Tina Beamon | F | - | 2 Jahre | |
| Bob Shopes | M | - |
Favrille, Inc.
| - |
| Igor Gorbatchevsky | M | - | 2 Jahre | |
| Jack Zwissig | M | 74 |
Favrille, Inc.
| - |
| Keith E. Anderson | M | 55 | 7 Jahre | |
| Robert McRae | M | 40 |
Viracta Subsidiary, Inc.
Viracta Subsidiary, Inc. BiotechnologyHealth Technology Viracta Subsidiary, Inc. engages in the development of proprietary viral gene activation therapy to address cancers associated with the Epstein-Barr virus. Its platform is designed as a targeted approach to treat a range of viral-associated cancers and other serious diseases. The company was founded by Ronald J. Berenson, Douglas V. Faller, George C. Hillman, Thalia Papayannopoulou, Susan P. Perrine, George Stamatoyannopoulos, and Robert Williams and is headquartered in Cardiff, CA. | - |
| Jeffrey Miner | M | - | 14 Jahre | |
| Dianne Baker | F | - |
Favrille, Inc.
| - |
| Robert D. Mass | M | 70 | 11 Jahre | |
| Lisa Rojkjaer | M | 58 |
Viracta Subsidiary, Inc.
Viracta Subsidiary, Inc. BiotechnologyHealth Technology Viracta Subsidiary, Inc. engages in the development of proprietary viral gene activation therapy to address cancers associated with the Epstein-Barr virus. Its platform is designed as a targeted approach to treat a range of viral-associated cancers and other serious diseases. The company was founded by Ronald J. Berenson, Douglas V. Faller, George C. Hillman, Thalia Papayannopoulou, Susan P. Perrine, George Stamatoyannopoulos, and Robert Williams and is headquartered in Cardiff, CA. | - |
| Miriam Cruz | F | - |
Viracta Subsidiary, Inc.
Viracta Subsidiary, Inc. BiotechnologyHealth Technology Viracta Subsidiary, Inc. engages in the development of proprietary viral gene activation therapy to address cancers associated with the Epstein-Barr virus. Its platform is designed as a targeted approach to treat a range of viral-associated cancers and other serious diseases. The company was founded by Ronald J. Berenson, Douglas V. Faller, George C. Hillman, Thalia Papayannopoulou, Susan P. Perrine, George Stamatoyannopoulos, and Robert Williams and is headquartered in Cardiff, CA. | 1 Jahre |
| George Spencer-Green | M | 77 |
Immunex Corp.
Immunex Corp. BiotechnologyHealth Technology Immunex Corporation is a leading biopharmaceutical company dedicated to improving lives through immune system science innovation | 4 Jahre |
| Vasant Prakash Gandhi | M | - |
Immunex Corp.
Immunex Corp. BiotechnologyHealth Technology Immunex Corporation is a leading biopharmaceutical company dedicated to improving lives through immune system science innovation | 1 Jahre |
| Mary Fisher | F | 62 |
Immunex Corp.
Immunex Corp. BiotechnologyHealth Technology Immunex Corporation is a leading biopharmaceutical company dedicated to improving lives through immune system science innovation | 4 Jahre |
| Paul J. Carter | M | - |
Immunex Corp.
Immunex Corp. BiotechnologyHealth Technology Immunex Corporation is a leading biopharmaceutical company dedicated to improving lives through immune system science innovation | 2 Jahre |
| Antonio J. Grillo-López | M | 84 |
Favrille, Inc.
| 8 Jahre |
| Bob Lorsch | M | 74 |
Favrille, Inc.
| - |
| James J. L'Italien | M | 71 | 5 Jahre | |
| Martin D. Meglasson | M | 74 | 6 Jahre | |
| Mark E. Erwin | M | 59 | 2 Jahre | |
| Randy Alan Kelley | M | 68 |
Immunex Corp.
Immunex Corp. BiotechnologyHealth Technology Immunex Corporation is a leading biopharmaceutical company dedicated to improving lives through immune system science innovation | 1 Jahre |
| Barry A. Labinger | M | 60 |
Immunex Corp.
Immunex Corp. BiotechnologyHealth Technology Immunex Corporation is a leading biopharmaceutical company dedicated to improving lives through immune system science innovation | 2 Jahre |
| David L. Guy | M | 61 |
Favrille, Inc.
| 4 Jahre |
| Brigette Roberts | M | - | 2 Jahre | |
| Maria Bedoya-Toro Munera | M | 72 | 3 Jahre | |
| Jessica Stone Rampton | F | 53 | 5 Jahre | |
| Mark D. Booth | M | 64 |
Immunex Corp.
Immunex Corp. BiotechnologyHealth Technology Immunex Corporation is a leading biopharmaceutical company dedicated to improving lives through immune system science innovation | 1 Jahre |
| David A. Mann | M | 65 |
Immunex Corp.
Immunex Corp. BiotechnologyHealth Technology Immunex Corporation is a leading biopharmaceutical company dedicated to improving lives through immune system science innovation | 7 Jahre |
| Wayne I. Roe | M | 73 |
Favrille, Inc.
| 8 Jahre |
| Richard M. Murawski | M | 75 |
Favrille, Inc.
| 6 Jahre |
| David L. Urdal | M | 74 |
Immunex Corp.
Immunex Corp. BiotechnologyHealth Technology Immunex Corporation is a leading biopharmaceutical company dedicated to improving lives through immune system science innovation | 13 Jahre |
| Fred Middleton | M | 74 |
Favrille, Inc.
| 7 Jahre |
| Paul Maier | M | 76 | 15 Jahre | |
| Thomas H. Silberg | M | 76 | 3 Jahre | |
| Taylor J. Crouch | M | 64 | 2 Jahre | |
| Daniel Loeb | M | 62 | 2 Jahre | |
| Michael L. Eagle | M | 76 |
Favrille, Inc.
| 6 Jahre |
| Jeffrey R. Perry | M | 65 | 4 Jahre | |
| David T. Molowa | M | 64 |
Favrille, Inc.
| 3 Jahre |
| Cam Garner | M | 75 |
Favrille, Inc.
| 9 Jahre |
| Bernard Stolar | M | 77 |
Favrille, Inc.
| - |
| Arda Minocherhomjee | M | 70 |
Favrille, Inc.
| 3 Jahre |
| Alice M. Wei | F | 60 |
Favrille, Inc.
| 6 Jahre |
| Benjamin Cadieux | M | - | 1 Jahre |
Statistik
| Land | Beziehungen | % des Gesamten |
|---|---|---|
| Vereinigte Staaten | 100 | 100,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Richard Ghalie
- Persönliches Netzwerk
